Form 4 for LFCR LIFECORE BIOMEDICAL, INC. DE
Accepted 2025-04-16 00:00:00 ET · period of report 2025-04-14 · accession 0001005286-25-000070 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-04-16 | 2025-04-14 | LFCR | Salus Thomas D. | Chief Legal, Administration | A - Grant | — | +215.0K | 215.0K | New | — |
| DM | 2025-04-16 | 2025-04-14 | LFCR | Salus Thomas D. | Chief Legal, Administration | A - Grant | $0.00 | +580.0K | 210.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-04-14 | A | A | 45,000 | — | 45,000 | D | — | — | (F1) The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. |
| 2 | Common | Common Stock | 2025-04-14 | A | A | 170,000 | — | 215,000 | D | — | — | (F1) The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. |
| 3 | Derivative | Performance-Based Restricted Stock Units | 2025-04-14 | A | A | 370,000 | $0.00 | 0 | D | — · — to 2030-04-14 | 370,000 Common Stock | (F3) Represents the maximum number of performance-based restricted stock units that can vest based on the Issuer's achievement of certain stock price milestones. (F2) Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. (F4) The performance-based restricted stock units vest, if at all, based on the Issuer's achievement of certain stock prices. |
| 4 | Derivative | Incentive Stock Option (Right to Buy) | 2025-04-14 | A | A | 210,000 | $0.00 | 210,000 | D | $6.17 · 2026-04-14 to 2032-04-14 | 210,000 Common Stock |